Edwards Lifesciences (EW) Revenue — Quarter Ended Jun 30, 2025
Revenue increased in the current quarter compared to the immediately preceding quarter and the same quarter one year earlier. The reporting period saw a notable year-over-year improvement in top-line performance.
Key takeaway
Quarter ended Jun 30, 2025 · FY2025 Q2
Revenue increased in the current quarter compared to the immediately preceding quarter and the same quarter one year earlier. The reporting period saw a notable year-over-year improvement in top-line performance.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.5B
Revenue reported for this quarter.
Quarter-over-quarter
+8.5%
Change from the immediately preceding quarter.
Year-over-year
+11.9%
Change from the comparable year-ago quarter.
Trailing four quarters
$5.7B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2024 | $1.4B | +11.9% |
| Dec 31, 2024 | $1.4B | +9.4% |
| Mar 31, 2025 | $1.4B | +6.2% |
| Jun 30, 2025 | $1.5B | +11.9% |
Revenue performance
The reported revenue reflects a positive direction, marking an increase from both the prior sequential period and the comparable period last year.
Quarterly comparison
The current quarter's revenue exceeded the immediately preceding quarter and was also higher than the same quarter one year earlier, continuing an upward trend observed in recent periods.
What to watch
No specific risk factors or management discussion were provided beyond standard forward-looking statements and liquidity details.